MYD88 and diffuse large B-cell lymphoma: Recently, mutations in MyD88 that cause the constitutive activation of the MyD88 signalling pathway have been identified as a major cause of the activated B-cell subtype of DLBCL (diffuse large B-cell lymphoma), one of the least curable forms of this blood cancer.